DE69735496D1 - Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Genen involviert - Google Patents

Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Genen involviert

Info

Publication number
DE69735496D1
DE69735496D1 DE69735496T DE69735496T DE69735496D1 DE 69735496 D1 DE69735496 D1 DE 69735496D1 DE 69735496 T DE69735496 T DE 69735496T DE 69735496 T DE69735496 T DE 69735496T DE 69735496 D1 DE69735496 D1 DE 69735496D1
Authority
DE
Germany
Prior art keywords
protein
administration
therapy
genes
intestinal cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69735496T
Other languages
English (en)
Other versions
DE69735496T2 (de
Inventor
Michael German
D Goldfine
S Rothman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69735496D1 publication Critical patent/DE69735496D1/de
Publication of DE69735496T2 publication Critical patent/DE69735496T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69735496T 1996-09-19 1997-09-18 Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Gene involviert Expired - Fee Related DE69735496T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US717084 1991-06-18
US08/717,084 US6225290B1 (en) 1996-09-19 1996-09-19 Systemic gene therapy by intestinal cell transformation
PCT/US1997/016523 WO1998011779A1 (en) 1996-09-19 1997-09-18 Delivery of therapeutic gene products by intestinal cell expression

Publications (2)

Publication Number Publication Date
DE69735496D1 true DE69735496D1 (de) 2006-05-11
DE69735496T2 DE69735496T2 (de) 2006-09-21

Family

ID=24880656

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735496T Expired - Fee Related DE69735496T2 (de) 1996-09-19 1997-09-18 Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Gene involviert

Country Status (10)

Country Link
US (4) US6225290B1 (de)
EP (1) EP0939590B1 (de)
JP (1) JP2001502303A (de)
AT (1) ATE320186T1 (de)
AU (1) AU729457B2 (de)
CA (1) CA2264744A1 (de)
DE (1) DE69735496T2 (de)
DK (1) DK0939590T3 (de)
ES (1) ES2256896T3 (de)
WO (1) WO1998011779A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US7749215B1 (en) * 1998-02-05 2010-07-06 Biosense, Inc. Intracardiac cell delivery and cell transplantation
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
EP1093457B8 (de) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
KR20010042069A (ko) * 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
BR9909918A (pt) * 1998-05-06 2000-12-26 Upjohn Co Método para a liberação de um hormÈnio de crescimento ou citocina de proteìna, peptìdeo ou polipeptìdeo fisiologicamente ativos a um vertebrado não-humano
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
EP1889914A1 (de) * 1999-02-19 2008-02-20 Engene, Inc. Zusammensetzungen für die Gentherapie von Diabetes
ATE374251T1 (de) * 1999-02-19 2007-10-15 Engene Inc Zusammensetzungen zur gentherapie von diabetes
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP1159415B1 (de) * 1999-03-04 2009-12-23 Revivicor, Inc. Genetische veränderung von somatischen zellen und deren verwendungen
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
CA2403205A1 (en) * 2000-03-13 2001-09-20 Engene, Inc. Compositions and methods of regulated protein expression in gut endocrine k cells
KR101215789B1 (ko) * 2000-03-30 2012-12-26 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
GB0010630D0 (en) * 2000-05-04 2000-06-21 Univ Wales Medicine Sequence
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU2001271621A1 (en) 2000-06-28 2002-01-08 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US20020151068A1 (en) * 2001-01-03 2002-10-17 Board Of Regents, The University Of Texas System Compositions and methods for the diagnosis and treatment of organophosphate toxicity
AU2002250032B2 (en) 2001-02-09 2008-06-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
WO2002080852A2 (en) * 2001-04-04 2002-10-17 Digital Gene Technologies, Inc. Genes expressed in intestinal epithelium and peyer's patch m cells
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
KR20030022094A (ko) * 2001-05-24 2003-03-15 (주)휴먼디엔에이테크놀로지 모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
US20050118719A1 (en) * 2001-11-07 2005-06-02 Schmidt Michael G. Nucleic acid delivery and expression
US20030135195A1 (en) * 2002-01-16 2003-07-17 Oscar Jimenez Highly lubricious hydrophilic coating utilizing dendrimers
DK1572127T4 (da) 2002-02-14 2014-11-24 Univ Leland Stanford Junior Enzymbehandling af fødevarer til cøliaki
AU2003265228A1 (en) * 2002-03-12 2003-12-22 Surface Logix, Inc. Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
US7374930B2 (en) * 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
ATE498403T1 (de) * 2002-05-31 2011-03-15 Childrens Hosp Medical Center Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
US7977098B2 (en) 2002-05-31 2011-07-12 Children's Hospital Medical Center Antigenic binding patterns of norovirus to human histo-blood group antigens
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
NZ539423A (en) * 2002-10-24 2006-12-22 Biogen Idec Inc Ferritin heavy chain gene locus vectors that include 5' and 3' sequences, which can convey high levels of expression to heterologous genes in stable transfectants
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
WO2005032574A1 (en) * 2003-10-03 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Modulation of gastrointestinal epithelium proliferation through the wnt signaling pathway
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
AU2006326937B2 (en) * 2005-12-20 2012-01-19 Cephalon Australia Pty Ltd Anti-inflammatory dAb
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
CA2706600A1 (en) * 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
CA2726193C (en) 2008-06-03 2018-11-27 University Of Rochester Methods of treating inflammatory intestinal disease and managing symptoms thereof
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100068283A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex VIVO modifiable particle or polymeric material medicament carrier
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
US8486421B2 (en) 2009-06-09 2013-07-16 Children's Hospital Medical Center Antigen-norovirus P-domain monomers and dimers, antigen-norovirus P-particle molecules, and methods for their making and use
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
HUE054471T2 (hu) 2014-04-01 2021-09-28 Rubius Therapeutics Inc Immunmodulációs módszerek és készítmények
US20160160229A1 (en) * 2014-12-09 2016-06-09 THC Farmaceuticals, Inc. Methods of producing antibody-rich cannabis and honeysuckle plants
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US6241982B1 (en) * 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
WO1990005787A1 (en) 1988-11-23 1990-05-31 The Regents Of The University Of California Position-specific insertion vectors and method of using same
DE69032284T2 (de) 1989-03-21 1998-10-08 Vical, Inc., San Diego, Calif. Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
WO1993019660A1 (en) * 1992-04-03 1993-10-14 Baylor College Of Medicine Gene therapy using the intestine
WO1994016057A1 (en) * 1992-12-31 1994-07-21 Dana-Farber Cancer Institute, Inc. Enhancer sequence for modulating expression in epithelial cells
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
EP0710288B1 (de) 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenovirale vektoren für die behandlung der hämophilie
US5681744A (en) * 1995-03-17 1997-10-28 Greenstein; Robert J. Delivery and expression of heterologus genes using upstream enhancer regions of mammalian gene promoters
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
AU6097896A (en) 1995-06-07 1996-12-30 Alza Corporation Oral delivery of gene constructs
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation

Also Published As

Publication number Publication date
US6225290B1 (en) 2001-05-01
DK0939590T3 (da) 2006-07-24
AU4422197A (en) 1998-04-14
US20020039574A1 (en) 2002-04-04
CA2264744A1 (en) 1998-03-26
US6831070B2 (en) 2004-12-14
EP0939590A1 (de) 1999-09-08
EP0939590B1 (de) 2006-03-15
ATE320186T1 (de) 2006-04-15
DE69735496T2 (de) 2006-09-21
EP0939590A4 (de) 2002-09-04
AU729457B2 (en) 2001-02-01
US20050026863A1 (en) 2005-02-03
WO1998011779A1 (en) 1998-03-26
JP2001502303A (ja) 2001-02-20
US6258789B1 (en) 2001-07-10
ES2256896T3 (es) 2006-07-16

Similar Documents

Publication Publication Date Title
DE69735496D1 (de) Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Genen involviert
Martin et al. Gene transfer to intact mesenteric arteries by electroporation
US5821235A (en) Gene therapy using the intestine
Amano et al. Anatomy and histology of rodent and human major salivary glands—Overview of the japan salivary gland society-sponsored workshop—
Hsu et al. Ontogeny of expression of transforming growth factor-β1 (TGF-β1), TGF-β3, and TGF-β receptors I and II in fetal rat fibroblasts and skin
Yin et al. Gene therapy for streptozotocin-induced diabetic mice by electroporational transfer of naked human insulin precursor DNA into skeletal muscle in vivo
AU666142B2 (en) Viral recombinant vectors for expression in muscle cells
JPH11502413A (ja) 分泌腺発現による遺伝子治療
Li et al. Gene therapy for psoriasis in the K14‐VEGF transgenic mouse model by topical transdermal delivery of interleukin‐4 using ultradeformable cationic liposome
JP2009526571A (ja) 遺伝子発現の熱的制御または電磁気的制御のための方法および遺伝子発現の熱的制御または電磁気的制御のための装置
EA005496B1 (ru) Растворимый гетеродимерный рецептор цитокина
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
Islamov et al. Epidural stimulation combined with triple gene therapy for spinal cord injury treatment
CN102462837A (zh) 抗炎组合物
Christ et al. The application of gene therapy to the treatment of erectile dysfunction
Islamov et al. New therapy for spinal cord injury: Autologous genetically-enriched leucoconcentrate integrated with epidural electrical stimulation
JP2001515713A (ja) 散在性の若しくはアクセス困難な細胞又は組織を有するヒト病状の処置又は診断方法
Zhang et al. Enhancement of bone regeneration by coadministration of angiogenic and osteogenic factors using messenger RNA
HUP0002913A2 (hu) Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára
CN113557036A (zh) 基因编辑以改善关节功能
Baum et al. The mouth is a gateway to the body: gene therapy in 21st century dental practice
CN108685850A (zh) 模块化组装的组合生物药物联合递送系统及应用
Morikawa et al. Impaired G‐CSF production at post‐transcriptional level in a patient with chronic idiopathic neutropenia
EP4022039B1 (de) Aktivierte mesenchymale stammzellen zur verwendung in der behandlung von gliedmassenischämie
Devin et al. Pleural space as a site of ectopic gene delivery: Transfection of pleural mesothelial cells with systemic distribution of gene product

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee